ERA NET COFUND JPI AMR –ACTION: “Disrupting drug Resistance Using Innovative Design (DRUID)»




Destination: Proposals should focus on licenced antimicrobial agents (antibiotics/antifungals) or agents under pre-clinical and/or early clinical development, and should address at least one of the following topics:

• Improvement of drug/plant protection agent efficacy and/or specificity through chemical modifications (including hit to lead optimisation)

• Drug/plant protection agent repurposing.

• Optimisation of drug/plant protection agent combinations, alone or with adjunct therapies (including therapeutic vaccines);

• Design and implementation of new strategies (including optimisation of drug doses) for improved application, efficacy and delivery of single or combinations of antimicrobials;

• Design and implementation of innovative tools, including novel chemistry and/or new materials for improved application, efficacy and delivery of antimicrobials.

Eligibility rules for the consortia are:

• The consortium must include a minimum of three (3) eligible partners asking for funding from three (3) different eligible countries (including at least two amongst EU Member States or Associated Countries).

• The consortium can include a maximum of six (6) project partners (including non-funded partners).


AEI: 0.8 M€

  • Up to 300,000 € per coordinator (including maximum 15% indirect costs).
  • Up to 200;000 € per partner (including maximum 15% indirect costs).

ISCIII: 1 M€ for funding 4-6 projects:

  • Up to 250,000 € per coordinator (including maximum 21% indirect costs).
  • Up to 175,000 € per partner (including maximum 21% indirect costs).

Duration: 3 years.

Estás interesado?

Llena el siguiente formulario para recibir más información: